Loading...
Please wait, while we are loading the content...
Similar Documents
Ibrutinib and lenalidomide: when 1+1 = >2
| Content Provider | Scilit |
|---|---|
| Author | Westin, Jason |
| Copyright Year | 2019 |
| Description | In this issue of Blood, Goy et al report on the promising activity of a phase 1b trial of the targeted therapy triplet rituximab, ibrutinib, and lenalidomide in patients with relapsed nongerminal center diffuse large B-cell lymphoma $(DLBCL).^{1}$ |
| Related Links | http://www.bloodjournal.org/content/bloodjournal/134/13/996.full.pdf |
| Ending Page | 998 |
| Page Count | 3 |
| Starting Page | 996 |
| DOI | 10.1182/blood.2019002237 |
| Journal | Blood |
| Issue Number | 13 |
| Volume Number | 134 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2019-07-22 |
| Access Restriction | Open |
| Subject Keyword | Hematology Relapsed Lymphoma Triplet Rituximab Ibrutinib Lenalidomide Promising Goy Journal: Blood (Vol- 123, Issue- 13) |
| Content Type | Text |
| Resource Type | Article |